WaveMan
WaveMan · Company
MREO · Mereo Biopharma Group Plc
> Search tickers & screens ⌘K
LIVE
← All companies

MREO Mereo BioPharma (MREO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001719714
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter

Mereo BioPharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Mereo BioPharma Group plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Scots-Knight Denise
Chief Executive Officer
SELL
2024-09-16 SECtraded 2024-09-13
60,046
$253.4K
-93.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 12, 2024.
  • The trade is 7.4% of the 808,921 shares held after it.
  • 5 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Scots-Knight Denise sold about $253.4K of MREO on Sep 13, 2024; 5 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Lewicki John A.
Chief Scientific Officer
SELL
2024-09-16 SECtraded 2024-09-13
10,937
$46.2K
-93.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 12, 2024.
  • The trade is 13.9% of the 78,630 shares held after it.
  • 5 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lewicki John A. sold about $46.2K of MREO on Sep 13, 2024; 5 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Sermon Charles
General Counsel
SELL
2024-09-16 SECtraded 2024-09-13
20,946
$88.4K
-93.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 12, 2024.
  • The trade is 9.6% of the 219,061 shares held after it.
  • 5 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Sermon Charles sold about $88.4K of MREO on Sep 13, 2024; 5 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Fox Christine Ann
Chief Financial Officer
SELL
2024-09-16 SECtraded 2024-09-13
19,158
$80.8K
-93.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 12, 2024.
  • The trade is 21.5% of the 89,285 shares held after it.
  • 5 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Fox Christine Ann sold about $80.8K of MREO on Sep 13, 2024; 5 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
Hughes-Wilson Alexandra
See Remarks
SELL
2024-09-16 SECtraded 2024-09-13
84,008
$354.5K
-93.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Sep 12, 2024.
  • The trade is 166.4% of the 50,475 shares held after it.
  • 5 other insiders sold within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Hughes-Wilson Alexandra sold about $354.5K of MREO on Sep 13, 2024; 5 other insiders sold within 30 days and 27 funds added in the latest 13F quarter.
25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 20 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 1.2 days to cover · settled 2026-09-30
below 83% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MREO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-86.2%12M
-88%-54%-19%+15%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MREO: institutional holders (13F)

13F holdings, latest reported quarter
Rubric Capital Management LP
15,307,347 sh
$4.9M
683 Capital Management, LLC
11,777,856 sh
$3.7M
BANK OF AMERICA CORP /DE/
8,195,281 sh
$2.6M
Defilade Capital Management, L.P.
7,558,756 sh
$2.4M
Newtyn Management, LLC
3,000,000 sh
$953.1K

Congress trades in MREO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MREO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MREO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) International Small Cap ETF
$42.8K position · as of 2026-06-30
0.0%
Blackstone Alternative Multi-Strategy Fund
$4.6K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$31.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.7M
-$2.0M
$1.2M
-44%
n/a
2024
$3.2M
$6.2M
$1.3M
+367%
n/a
2023
$2.2M
$5.4M
$1.0M
+208%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MREO financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$25.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+134.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+114.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-81.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-11.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$500.0K$0$10.0M$0
Operating income-$40.1M-$47.4M-$28.4M-$54.4M
Net income$41.9M$43.3M$29.5M-$42.2M
EPS (diluted)-0.05-0.06-0.04-0.07
Operating cash flow-$31.0M-$32.8M-$21.1M-$48.8M
Cash$41.0M$69.8M$57.4M$68.2M
SEC XBRL, fiscal years, as known on 2026-10-28

MREO Stock Sonar score 3/7 axes

Find similar shapesCompare

MREO ranks highest on profitability (76th percentile) and risk and compliance (68th), and lowest on institutional and government (37th), among Pharma & Biotech peers.

Profitability
76
Inputs
  • Return on equity+134.4% · 98 pct, sector of 545
  • Return on assets+114.3% · 98 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-81.3% · 32 pct, sector of 576
Institutional and government
37
Inputs
  • Funds adding, latest quarter27 · 37 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
68
Inputs
  • Short interest, % of float+2.1% · 73 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.2% · 63 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies